2nd USFDA Inspection of Formulation facility successfully completed with Zero 483’s in February 2018
Expansion of Oncology block to meet growing market demand
WHO-GMP Inspection of Formulation facility successfully completed in November 2017
5th USFDA Inspection of API facility successfully completed with Zero 483 observations in November 2017
3rd EUGMP inspection of API facility successfully completed in September 2017
1st USFDA Inspection of the Formulation facility successfully completed in July 2017
Launched Domestic Business Operation into super specialty segments like Immunology, Transplant Medicine & Chronic Kidney Disease segment.
Commissioned Formulation Manufacturing Facility at Valthera, Ahmedabad, India.
Granted FDA-India manufacturing licenses for FDF facility at Valthera, Ahmedabad, India
Established a state-of-the-art facilities to indigenously develop and manufacture Finished Drug Formulations at Valthera, Ahmedabad, Gujarat, India
Laid foundation stone for new Manufacturing facility at Valthera, Ahmedabad.
4th USFDA Inspection successfully completed at Dholka Site, Ahmedabad.
Filed submission for APIs DIL, China
Second EU GMP inspection conducted in May 2014
Commissioned Manufacturing Block No. 22.
|2011 to 2013||
Renewed Japanese AFM
3rd USFDA inspection in August 2012
Commissioned Block 20 & 21
Korean FDA inspection
Commissioned Block 19 for Oncology APIs with isolators to handle API and dedicated QC
Commissioned stand alone Manufacturing Blocks 17 & 18 for Lyophilization & Hydrogenation Respectively
CRAM activities initiated with major biopharmaceuticals company in areas of natural/semi-synthetic products
Commissioned Manufacturing Block 4A
First EU GMP inspection in April 2011
|2008 to 2010||
Existing share holders buyback Matrix/Mylan’s entire equity holding
Entry of Mycophenolate Mofetil & Tacrolimus in US generic market as a front runner
Commissioned Manufacturing Blocks 7, 8, 11, 12, 14, 15 & 16, enhancing fermentation & downstream capacities.
2nd USFDA inspection in March, 2008
|2005 to 2007||
Equity partnership by Matrix Laboratories
Fermentation capacity doubled
Commissioned Manufacturing Block 3, 4, 5 & 6
1st USFDA inspection for its Biotech facility
|2001 to 2004||
Commissioned Manufacturing Block 2 & started commercial production.
Initiated development & production of 1st Immunosuppressant
First DMF/ COS filed by Concord.
Scrapped small chemical unit & bought Biotech equipments & started production of Amidase Enzyme
|1989 to 2000||
Mr. Sudhir Vaid took over from DSM and named it CONCORD BIOTECH LIMITED
Taken over by DSM (formerly known as Max GB)
Promoted by Sanofi (formerly known as Hoechst)